Effect of Prophylactic Fibrinogen Concentrate In Scoliosis Surgery

Brno University Hospital32 enrolled

Overview

EFISS is a prospective, randomized, placebo-controlled trial testing the feasibility, safety and efficacy of prophylactic administration of fibrinogen in paediatric spinal surgery. The study is monocentric and will be conducted in University Hospital Brno, Czech Republic. This is a pilot study in which the primary objective will be to evaluate the feasibility of a clinical trial in 32 selected patients undergoing scoliosis surgery. Participants will be randomized into study groups in a 1:1 allocation ratio and followed up for 28 days after surgery. The expected duration of this clinical trial is 8 months.

Scoliosis is an abnormal lateral curvature of the spine. It is most commonly diagnosed in childhood and early adolescence. Surgical treatment is indicated for severe scoliosis to reduce back pain, neurological symptoms and prevent deterioration of respiratory and cardiovascular function. Scoliosis surgery is often accompanied by a large blood loss and blood transfusion is necessary in 30% to 60% of operated patients. The limited availability, high cost and risk of complications associated with the administration of transfusion products has led to efforts to introduce procedures that aim to reduce the magnitude of blood loss during surgery. Fibrinogen plays an important role in coagulum formation and bleeding arrest. Insufficient fibrinogen levels lead to impaired blood clotting and increased bleeding during major surgery. It has also been shown that patients with higher preoperative fibrinogen levels have less perioperative blood loss. Prophylactic administration of fibrinogen leads to a reduction in blood loss and the number of transfusions administered in some types of procedures. Prophylactic administration of fibrinogen at a dose of 30 mg/kg has been shown to be safe even in paediatric patients. Whether prophylactic fibrinogen administration before scoliosis surgery has an effect on the magnitude of blood loss is unclear. To plan a sufficiently large randomized trial to clarify the effect of prophylactic fibrinogen administration before elective scoliosis surgery on the magnitude of blood loss, and the need for transfusion administration, our team of investigators decided to organize this pilot study. Prophylactic administration of fibrinogen has been widely described in various indications in recent decades. Among others, it is mainly cardiovascular surgery, where some authors refer the absence of the effect of fibrinogen administration on postoperative bleeding and some even the association with increased allogeneic blood product transfusion. On the contrary, one-hundred sixteen patients undergoing heart surgery with an expected cardiopulmonary bypass were part of the placebo-controlled double-blind study in which fibrinogen concentrate significantly reduced postoperative bleeding with a significant reduction in allogeneic blood products transfusions. Reduction of bleeding after coronary artery bypass graft without signs of postoperative hypercoagulability associated with preoperative infusion of fibrinogen concentrate is descibed. Fibrinogen administration has also been tested in double-blind placebo-controlled clinical trials associated with urologic surgery and gynaecological surgery procedures. Regarding skeletal surgery, the effect of prophylactically administered fibrinogen on postoperative bleeding has also been studied. Intraoperative administration of fibrinogen was successfully used to significantly decrease bleeding and transfusions in 30 children aged 6 months to 17 years undergoing craniosynostosis surgery. Compared to these results, no differences in blood loss and transfusion requirements were found between treated and placebo groups in younger paediatric patients up to 25 months during craniofacial surgery. Clinical trials directly related to spinal surgery have also been described. This clinical study was performed in 30 adult patients undergoing lumbar surgery, in which 1g of fibrinogen dissolved in distilled water was injected near the surgical incision in the intervention group (n=15). Bleeding during and after surgery in the control group was significantly higher than in the intervention group (P\<0.05), and therefore the efficacy of fibrinogen was demonstrated in this indication. Efficacy and safety of preoperatively administrated fibrinogen concentrate (30 mg / kg to 2 g maximum) have also been confirmed in the paediatric population. A total of 102 children (12 - 18 years) with idiopathic scoliosis undergoing surgery were randomized to test and control groups (n=51), where fibrinogen infusion reduced median perioperative bleeding by approximately 155 ml compared to placebo. Fibrinogen administrated in the test group in this case did not reduce the amount of allogeneic blood product transfusion. The clinical outcome of an individual participant in the prophylactic administration of fibrinogen prior to scoliosis surgery may or may not be improved. If effective, this administration will reduce blood loss during surgery and reduce the need for blood transfusions. In any case, participation in this study will improve knowledge about the prophylactic use of fibrinogen during scoliosis surgery, and all participants in this study will contribute to this socially beneficial knowledge. The same surgical procedure will be used in both study groups as is standard in the surgical treatment of spinal scoliosis. The method is generally well tolerated by patients and does not pose significant risks. The potential risks of participating in the EFISS study may include the rare development of adverse reactions, including fever, allergic and anaphylactic reactions, or thromboembolic events associated with the administration of investigational medicinal product.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

Interventions

Fibrinogen Concentrate HumanDRUG

Patients in the intervention group will receive single administration of fibrinogen concentrate intravenously at a dose of 20-30 mg/kg (depending on body weight and clinical condition, according to SmPC). The medicinal product will be diluted in a 100 ml infusion bag and administered after induction of anaesthesia prior beginning of surgery. The infusion rate should not exceed approximately 5 ml per minute.

Eligibility

Sex: ALLMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Subjects will be eligible for the trial if they meet all of the following criteria: 1. Age \< 18 years of age at the time of enrolment 2. Elective scoliosis surgery 3. Signed the relevant informed consent form (more in Chapter 10.1) 4. Sexually active participants (≥ 15 years old) must agree to the use of following methods of contraception for the duration of this clinical trial: 1. Women - proper use of a highly reliable method of contraception, i.e. combined hormonal contraception (oral, vaginal or transdermal form), gestagen hormonal contraceptives associated with ovulation inhibition (oral or injectable form) or sexual abstinence. 2. Men - sexual abstinence or the use of an adequate contraceptive method (i.e. condom) in case of sexual intercourse. Exclusion Criteria: Subjects will not be eligible for the trial if they meet any of the following criteria: 1. Diagnosed congenital or acquired coagulopathy 2. Use of anticoagulants with the exception of perioperative prophylactic administration of Low molecular weight heparin (LMWH) to prevent venous thromboembolism (VTE) 3. Known hypersensitivity to the active substance or to any of the excipients of Investigational Medicinal Product (IMP) 4. History of deep vein thrombosis or pulmonary embolism 5. Pregnancy and lactation

Locations (1)

University Hospital Brno

Brno, Czechia

RECRUITING

Outcomes

Primary Outcomes

Adverse event

The following primary endpoint will be monitored to evaluate the primary objective: Adverse event - Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.

Time frame: through study completion, an average of 6 months

Adverse drug reaction

The following primary endpoint will be monitored to evaluate the primary objective: Adverse drug reaction - All untoward and unintended responses to an investigational medicinal product related to any dose administered

Time frame: through study completion, an average of 6 months

Serious adverse event and reaction

The following primary endpoint will be monitored to evaluate the primary objective: Serious adverse event and reaction - A serious adverse event/reaction is any untoward medical occurrence or effect that at any dose: * Results in death; * Is life-threatening; * Requires hospitalization or extension of existing hospitalization; * Results in persistent or significant disability or incapacity; * Is a congenital anomaly or birth defect

Time frame: through study completion, an average of 6 months

Unexpected adverse reaction

The following primary endpoint will be monitored to evaluate the primary objective: Unexpected adverse reaction - Adverse reaction, the nature, severity, or outcome of which

Time frame: through study completion, an average of 6 months

Suspected unexpected serious adverse reaction

The following primary endpoint will be monitored to evaluate the primary objective: Suspected unexpected serious adverse reaction - Any suspected adverse reaction related to the study treatment that is both serious and unexpected.

Time frame: through study completion, an average of 6 months

Secondary Outcomes

Deep-vein thrombosis

Incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) ▪ Deep-vein thrombosis verified on duplex ultrasound imaging (YES/NO)

Time frame: through study completion, an average of 6 months

Pulmonary embolism

Incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) ▪ Pulmonary embolism confirmed on CT (YES/NO)

Time frame: through study completion, an average of 6 months

Infection or healing disorder

Incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) ▪ Infection or healing disorder requiring re-surgery and / or initiation of antibiotic therapy (YES/NO)

Time frame: through study completion, an average of 6 months

Length of stay

▪ Length of stay (LOS) - day of admission - day of discharge will be counted as 1 day

Time frame: through study completion, an average of 6 months

ICU length of stay

▪ ICU length of stay (ICU LOS) - day of admission - day of discharge will be counted as 1 day

Time frame: through study completion, an average of 6 months

28-day mortality

▪ 28-day mortality (number of patients who are not alive 28 days after randomization)

Time frame: at day 28 of study

Age

Comparison of demographic characteristics between study groups ▪ Age (years)

Time frame: at the start of the study

Sex

Comparison of demographic characteristics between study groups ▪ Sex (male, female)

Time frame: at the start of study

Central Contacts

Roman Gal, prof.

CONTACT

532233850 gal.roman@fnbrno.cz

Ondrej Hrdy, MD

CONTACT

532232305 hrdy.ondrej@fnbrno.cz

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Weight

Comparison of demographic characteristics between study groups ▪ Weight (kilograms)

Time frame: at the start of study

Haemoglobin

Comparison of laboratory values of selected haematological parameters between study groups ▪ Haemoglobin (g/l; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Haematocrit groups

Comparison of laboratory values of selected haematological parameters between study ▪ Haematocrit (%; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Platelet count

Comparison of laboratory values of selected haematological parameters between study groups ▪ Platelet count (n/l; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Fibrinogen

Comparison of laboratory values of selected haematological parameters between study groups ▪ Fibrinogen (g/l; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Activated parcial thromboplastin time (aPTT)

Comparison of laboratory values of selected haematological parameters between study groups ▪ aPTT (s; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Prothrombin time (PT)

Comparison of laboratory values of selected haematological parameters between study groups ▪ PT (s; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Thrombin time (TT)

Comparison of laboratory values of selected haematological parameters between study groups ▪ TT (s; before, at the end of surgery and 24 hours after surgery)

Time frame: before surgery, immediately after surgery and 24 hours after surgery

Total volume of blood loss

Comparison of blood loss level and its compensation between study groups ▪ Total volume of blood loss (ml; during surgery and in the 24-hour postoperative period)